Highlights by Tian Zhang from ASCO GU25
The 2025 ASCO Genitourinary (GU) Cancers Symposium takes place from February 13 to 15, featuring interactive sessions focused on cutting-edge research, multidisciplinary expertise, and evidence-based practices in GU cancer care. ASCO, the American Society for Radiation Oncology, and the Society of Urologic Oncology cosponsor the symposium.
Tian Zhang, Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, shared some insights from the Symposium:
“Neeraj Agarwal presents final OS from TALAPRO2 trial”
“Neeraj Agarwal presents final overall survival from TALAPRO2 trial – patients w metastatic #prostatecancer lived longer and had improved time to chemo. Only 2 MDS/AML events in entire trial. Supporting the talazoparib-enzalutamide approval.”
“Tribute to Felix Feng.
Feng Symposium kicks off with Himanshu Nagar, Misha Beltran, ASCO, and President-elect Eric Small at the helm.
Announcing the endowed ASCO YIA, fostering future scientists and science in prostate cancer.
We miss you, Felix.
Love to Mary Feng and family today.”
“Tanya Dorff’s discussion for metastatic prostate cancer”
“Tanya Dorff always thoughtful with discussion for metastatic prostate cancer – buckets of treatments – doublets, triplets, XRT, including trials! TRIPLESWITCH, ADREAM, S1802, and more!”
“Tom Powles with nice EV302 follow-up data”
“Tom Powles with nice EV302 follow-up data of enfortumab vedotin and pembrolizumab in bladder cancer. Duration of response is excellent. Our patients are living longer with better responses.”
“Iyer Gopa with first look at LOXO435”
“Iyer Gopa with first look at LOXO435 – nice activity for FGFR3 inhibition and low AE rate. Our patients at UTSW Simmons Cancer Center benefited from this trial!”
“Samra with comprehensive perspective of future biomarkers”
“Turajlic Lab’s Samra with comprehensive perspective of future biomarkers to help us understand disease heterogeneity.
Her spatial/temporal work is excellent. Highlights James Brugarolas’ work on BAP1 loss and OPTICRCC Brian Rini which is open and enrolling UTSW Simmons Cancer Center!”
“Elizabeth Plimack on NIAGARA ‘sandwich’ and Checkmate274”
“Elizabeth Plimack with killer discussion setting the scene for the NIAGARA ‘sandwich’ and Checkmate274, both practice changing for our patients with bladder cancer.”
“Matt Milowsky with updated Checkmate274 trial”
“Matt Milowsky with updated Checkmate274 trial – adjuvant nivolumab after cystectomy improves time to recurrence and overall survival in bladder cancer. Sets up ongoing Alliance for Clinical Trials in Oncology’ sMODERN trial!”
“Great last session ASCO GU25”
“Great last session ASCO GU25 – interactive case based discussions for hard to treat kidney cancer. Good to see Raquibul Hannan representing UTSW Radiation Oncology on expert panel, along with friends Maite Bourlon, Matt Campbell, Viraj Master.”
More posts featuring Tian Zhang and ASCO GU25.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023